A randomised trial of post operative radiation therapy following wide excision of neurotropic melanoma of the head and neck

This trial is suitable for people that have been diagnosed with an unusual form of melanoma known as neurotropic melanoma. Neurotropic melanoma is characterised by the presence of melanoma cells around nerve sheaths or within nerves. When this type of melanoma is diagnosed on the head or neck region the standard treatment is surgery. This disease may have a high rate of local relapse (recurrence of melanoma in the same area) after surgery. In some hospitals, immediate post-operative radiotherapy is already the standard treatment, but in other hospitals it is not. It is not known for certain whether the benefits of radiotherapy outweigh the risks. The purpose of this trial is to investigate if having radiation therapy soon after surgery is better at preventing the melanoma recurrence than just having surgery alone.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

50

Closing Date of Accrual

January 2020

Trial Chairperson

A/Prof Matthew Foote, Princess Alexandra Hospital, QLD

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Related Post

Dr Anna Lawless, EI SIG Chair 2025
10 December, 2025

Shaping the future: How TROG’s Emerging Investigators group is breaking down barriers for new researchers

SPECIAL INTEREST GROUP IN FOCUS: 10 December 2025 Dr

9 December, 2025

TROG’s inaugural Km’s for Cancer Research brings community together to support our work

LATEST NEWS: 9 December 2025 As we wrap up